Core Viewpoint - Tiziana Life Sciences has submitted its seventh annual Development Safety Update Report (DSUR) to the FDA, reporting no drug-related serious adverse events for its lead candidate, intranasal foralumab, after 37.4 patient-years of cumulative exposure, emphasizing its safety profile in treating neuroinflammatory diseases [1][2][3]. Group 1: Safety and Efficacy of Foralumab - The DSUR indicates that there have been no serious adverse events attributed to intranasal foralumab, reinforcing its safety in clinical trials [2][3]. - The cumulative exposure of 37.4 patient-years demonstrates significant clinical experience with intranasal foralumab in central nervous system (CNS) indications [3][4]. - Adverse events reported were consistent with previous studies, and no new risks were identified that would require protocol modifications [3][4]. Group 2: Comparison with Other Treatments - The safety profile of intranasal foralumab aligns with prior studies of intravenous foralumab, which had been associated with infusion-related reactions, unlike the nasal delivery method that showed improved tolerability [4][10]. - The recent FDA denial of Sanofi's tolebrutinib for non-active secondary progressive multiple sclerosis (naSPMS) due to toxicity highlights the need for safer therapies in the neuroinflammatory disorder space [2][8]. Group 3: Clinical Development and Future Trials - Tiziana is conducting a Phase 2 trial of foralumab in naSPMS, with results expected in 2026 [2][5]. - Currently, 14 patients with naSPMS have been treated in an Expanded Access Program, showing either improvement or stability of disease within six months [5][9]. - Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development, representing a novel approach to treating neuroinflammatory and neurodegenerative diseases [6][10].

Core Insights - Tiziana Life Sciences has initiated its first patient dosing in an early Alzheimer's disease Phase 2 trial, marking a significant milestone for the company [1][4] - The FDA has approved the inclusion of both drug-naive patients and those previously treated with anti-amyloid therapies in the trial [1][7] Company Developments - The lead candidate, foralumab, is a fully human monoclonal antibody targeting CD3, aimed at reducing neuroinflammation associated with various neurodegenerative diseases [2][5] - Tiziana currently has three Phase 2 trials in progress for secondary progressive multiple sclerosis (SPMS), multiple system atrophy (MSA), and Alzheimer's, with a fourth trial for ALS expected to start in January [2][6] - Topline data readouts for all ongoing trials are anticipated in 2026, although the ALS study may extend into early 2027 depending on enrollment [2][10] Trial Details - The Phase 2 trial for Alzheimer's aims to assess the effects of foralumab both as a standalone treatment and in conjunction with existing anti-amyloid therapies [6][7] - The company believes that patients on anti-amyloid therapies still experience significant neuroinflammation, which they hope to address with foralumab [8] - The SPMS trial is particularly noteworthy as there are currently no approved therapies for this condition, and the company has received fast track designation from the FDA for this indication [9][10]

Core Viewpoint - Tiziana Life Sciences is advancing its lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, which has shown promising results in treating neuroinflammatory and neurodegenerative diseases, particularly in patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) [1][2][3]. Group 1: Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies using transformational drug delivery technologies [4]. - The company’s lead candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development, demonstrating a favorable safety profile and clinical response in previous studies [4]. - Tiziana's intranasal approach aims to improve efficacy, safety, and tolerability compared to traditional intravenous delivery methods [4]. Group 2: Product Development - Foralumab has been administered to 14 patients with na-SPMS in an open-label Expanded Access Program, with all patients showing either improvement or stability of disease within six months [2]. - The drug is also undergoing a Phase 2a randomized, double-blind, placebo-controlled trial to further assess its efficacy in patients with non-active secondary progressive multiple sclerosis [2][3]. - The immunomodulation potential of intranasal foralumab represents a novel treatment avenue for neuroinflammatory and neurodegenerative diseases [3]. Group 3: Executive Actions - Mr. Gabriele Cerrone, the Executive Chairman and Founder of Tiziana, has purchased 97,687 common shares, increasing his total holdings to 43,374,830 shares, which constitutes 36.08% of the company's issued share capital [1].

Core Viewpoint - Tiziana Life Sciences is celebrating a significant milestone by ringing the Nasdaq Closing Bell, highlighting its advancements in immunomodulation therapies, particularly its lead candidate, intranasal foralumab, which targets neurodegenerative and inflammatory diseases [1][2][3]. Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies using transformational drug delivery technologies, specifically intranasal delivery methods [6]. - The company’s lead candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development, showing a favorable safety profile and clinical response in patients [5][6]. Product Development - Intranasal foralumab aims to improve efficacy, safety, and tolerability compared to traditional intravenous methods, targeting diseases such as multiple sclerosis, Alzheimer's disease, and ALS [2][6]. - The company has recently achieved significant milestones, including the dosing of the first patient in its Phase 2 Alzheimer's trial and expansions in other key studies [3][4]. Clinical Trials - Foralumab has been administered to 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) in an open-label program, with all patients showing either improvement or stability of disease within six months [4]. - The drug is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled trial for non-active secondary progressive multiple sclerosis [4].

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for being a forward-looking technology adopter, utilizing decades of expertise and experience among its content creators [4] - The company employs automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]

Core Viewpoint - Tiziana Life Sciences has initiated a Phase 2 clinical trial for intranasal foralumab, targeting early Alzheimer's disease, marking a significant step in exploring immunomodulatory therapies for neuroinflammation [1][3][7]. Group 1: Clinical Trial Details - The Phase 2 trial is randomized and placebo-controlled, assessing the safety, tolerability, and potential efficacy of intranasal foralumab as both a monotherapy and in combination with FDA-approved anti-amyloid therapies, lecanemab or donanemab [4]. - Primary endpoints of the trial include neuroinflammation measured by TSPO-PET imaging, cognitive function, and changes in amyloid and tau biomarkers, with interim data expected in 2026 [4]. Group 2: Scientific Rationale - TSPO-PET imaging data indicates persistent microglial activation in Alzheimer's patients, even after treatment with anti-amyloid therapies, highlighting the need for therapies that address residual neuroinflammation [2]. - Intranasal foralumab is designed to modulate immune responses and reduce activated microglia, potentially slowing disease progression in early Alzheimer's disease [2][3]. Group 3: Company Insights - Gabriele Cerrone, Chairman & Founder, emphasized the importance of this trial in exploring a novel approach to Alzheimer's treatment, building on previous data showing foralumab's ability to reduce microglial activation in multiple sclerosis patients [3]. - Ivor Elrifi, CEO, expressed enthusiasm for the rapid progress from enrollment to first patient dosing, reflecting the urgent need for new treatment strategies beyond amyloid clearance [3]. Group 4: About Foralumab - Foralumab is a fully human anti-CD3 monoclonal antibody that stimulates T regulatory cells when administered intranasally, with previous studies showing positive outcomes in patients with non-active secondary progressive multiple sclerosis [5][6]. - It is the only fully human anti-CD3 monoclonal antibody currently in clinical development, representing a novel treatment avenue for neuroinflammatory and neurodegenerative diseases [6]. Group 5: Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies using alternative drug delivery technologies, aiming to improve efficacy, safety, and tolerability compared to traditional intravenous delivery methods [6][8].

Core Viewpoint - Tiziana Life Sciences has announced the withdrawal of its proposed public offering of common shares due to unfavorable market conditions [1]. Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative immunomodulation therapies, particularly through its lead candidate, intranasal foralumab, which is a fully human anti-CD3 monoclonal antibody [3]. - The company aims to improve the efficacy, safety, and tolerability of immunotherapy by utilizing alternative drug delivery methods, specifically through nasal administration [3]. - Tiziana's technology for alternative routes of immunotherapy has been patented, with several applications pending, indicating potential for broad pipeline applications [3]. Product Information - Foralumab is the only fully human anti-CD3 monoclonal antibody currently in clinical development, showing promise in stimulating T regulatory cells when administered intranasally [5][6]. - In an open-label intermediate-sized Expanded Access Program, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been treated, with all patients showing either improvement or stability of disease within six months [5]. - Foralumab is also undergoing a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial for patients with non-active secondary progressive multiple sclerosis [5].

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Viewpoint - Tiziana Life Sciences has initiated enrollment for a Phase 2 clinical trial of intranasal foralumab, targeting early Alzheimer's disease, with the first patient expected to be dosed next week [1][10]. Group 1: Clinical Trial Details - The Phase 2 trial will assess intranasal foralumab as both a monotherapy and in combination with FDA-approved anti-amyloid therapies, lecanemab or donanemab, in early Alzheimer's patients [2][9]. - Baseline assessments including cognitive testing and TSPO-PET imaging have been completed for initial participants [2][11]. - Key endpoints of the trial will include measures of neuroinflammation, cognitive function, and changes in biomarkers related to amyloid and tau pathology [11]. Group 2: Scientific Insights - New TSPO-PET imaging evidence shows persistent microglial activation in an Alzheimer's patient treated with lecanemab, indicating ongoing neuroinflammation despite amyloid plaque reduction [3][4]. - Dr. Howard Weiner emphasized that clearing amyloid does not eliminate the brain's inflammatory response, suggesting that intranasal foralumab may effectively address this residual neuroinflammation [6][10]. Group 3: Mechanism of Action - Intranasal foralumab is designed to induce regulatory T cells to migrate to the brain, potentially calming activated microglia and reducing neuroinflammation [6][10]. - The therapy aims to provide an additive or synergistic benefit when used alongside anti-amyloid treatments by targeting both amyloid pathology and persistent microglial inflammation [9][10]. Group 4: Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies using alternative drug delivery technologies, with intranasal foralumab being the only fully human anti-CD3 monoclonal antibody in clinical development [13]. - The company aims to improve efficacy, safety, and tolerability of treatments compared to traditional intravenous delivery methods [13].

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for being a forward-looking technology adopter, utilizing technologies to assist and enhance workflows [4] - The company employs automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]